IBDEI04S ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1550,2)
 ;;=^5049423
 ;;^UTILITY(U,$J,358.3,1551,0)
 ;;=T36.94XA^^14^156^74
 ;;^UTILITY(U,$J,358.3,1551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1551,1,3,0)
 ;;=3^Poisoning by unsp systemic antibiotic, undetermined, init
 ;;^UTILITY(U,$J,358.3,1551,1,4,0)
 ;;=4^T36.94XA
 ;;^UTILITY(U,$J,358.3,1551,2)
 ;;=^5049427
 ;;^UTILITY(U,$J,358.3,1552,0)
 ;;=T36.94XD^^14^156^75
 ;;^UTILITY(U,$J,358.3,1552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1552,1,3,0)
 ;;=3^Poisoning by unsp systemic antibiotic, undetermined, subs
 ;;^UTILITY(U,$J,358.3,1552,1,4,0)
 ;;=4^T36.94XD
 ;;^UTILITY(U,$J,358.3,1552,2)
 ;;=^5049428
 ;;^UTILITY(U,$J,358.3,1553,0)
 ;;=T36.94XS^^14^156^76
 ;;^UTILITY(U,$J,358.3,1553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1553,1,3,0)
 ;;=3^Poisoning by unsp systemic antibiotic, undetermined, sequela
 ;;^UTILITY(U,$J,358.3,1553,1,4,0)
 ;;=4^T36.94XS
 ;;^UTILITY(U,$J,358.3,1553,2)
 ;;=^5049429
 ;;^UTILITY(U,$J,358.3,1554,0)
 ;;=T36.5X6A^^14^156^77
 ;;^UTILITY(U,$J,358.3,1554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1554,1,3,0)
 ;;=3^Underdosing of aminoglycosides, initial encounter
 ;;^UTILITY(U,$J,358.3,1554,1,4,0)
 ;;=4^T36.5X6A
 ;;^UTILITY(U,$J,358.3,1554,2)
 ;;=^5049361
 ;;^UTILITY(U,$J,358.3,1555,0)
 ;;=T36.5X6D^^14^156^79
 ;;^UTILITY(U,$J,358.3,1555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1555,1,3,0)
 ;;=3^Underdosing of aminoglycosides, subsequent encounter
 ;;^UTILITY(U,$J,358.3,1555,1,4,0)
 ;;=4^T36.5X6D
 ;;^UTILITY(U,$J,358.3,1555,2)
 ;;=^5049362
 ;;^UTILITY(U,$J,358.3,1556,0)
 ;;=T36.5X6S^^14^156^78
 ;;^UTILITY(U,$J,358.3,1556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1556,1,3,0)
 ;;=3^Underdosing of aminoglycosides, sequela
 ;;^UTILITY(U,$J,358.3,1556,1,4,0)
 ;;=4^T36.5X6S
 ;;^UTILITY(U,$J,358.3,1556,2)
 ;;=^5049363
 ;;^UTILITY(U,$J,358.3,1557,0)
 ;;=T45.1X6A^^14^156^80
 ;;^UTILITY(U,$J,358.3,1557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1557,1,3,0)
 ;;=3^Underdosing of antineoplastic and immunosup drugs, init
 ;;^UTILITY(U,$J,358.3,1557,1,4,0)
 ;;=4^T45.1X6A
 ;;^UTILITY(U,$J,358.3,1557,2)
 ;;=^5051029
 ;;^UTILITY(U,$J,358.3,1558,0)
 ;;=T45.1X6D^^14^156^81
 ;;^UTILITY(U,$J,358.3,1558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1558,1,3,0)
 ;;=3^Underdosing of antineoplastic and immunosup drugs, subs
 ;;^UTILITY(U,$J,358.3,1558,1,4,0)
 ;;=4^T45.1X6D
 ;;^UTILITY(U,$J,358.3,1558,2)
 ;;=^5051030
 ;;^UTILITY(U,$J,358.3,1559,0)
 ;;=T45.1X6S^^14^156^82
 ;;^UTILITY(U,$J,358.3,1559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1559,1,3,0)
 ;;=3^Underdosing of antineoplastic and immunosup drugs, sequela
 ;;^UTILITY(U,$J,358.3,1559,1,4,0)
 ;;=4^T45.1X6S
 ;;^UTILITY(U,$J,358.3,1559,2)
 ;;=^5051031
 ;;^UTILITY(U,$J,358.3,1560,0)
 ;;=T36.8X6A^^14^156^83
 ;;^UTILITY(U,$J,358.3,1560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1560,1,3,0)
 ;;=3^Underdosing of other systemic antibiotics, initial encounter
 ;;^UTILITY(U,$J,358.3,1560,1,4,0)
 ;;=4^T36.8X6A
 ;;^UTILITY(U,$J,358.3,1560,2)
 ;;=^5049415
 ;;^UTILITY(U,$J,358.3,1561,0)
 ;;=T36.8X6D^^14^156^84
 ;;^UTILITY(U,$J,358.3,1561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1561,1,3,0)
 ;;=3^Underdosing of other systemic antibiotics, subs encntr
 ;;^UTILITY(U,$J,358.3,1561,1,4,0)
 ;;=4^T36.8X6D
 ;;^UTILITY(U,$J,358.3,1561,2)
 ;;=^5049416
 ;;^UTILITY(U,$J,358.3,1562,0)
 ;;=T36.8X6S^^14^156^85
 ;;^UTILITY(U,$J,358.3,1562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1562,1,3,0)
 ;;=3^Underdosing of other systemic antibiotics, sequela
 ;;^UTILITY(U,$J,358.3,1562,1,4,0)
 ;;=4^T36.8X6S
 ;;^UTILITY(U,$J,358.3,1562,2)
 ;;=^5049417
